<DOC>
	<DOCNO>NCT00540605</DOCNO>
	<brief_summary>A new approach HIV prevention currently study include use topical microbicides , substance kill microbe . The purpose study determine level tenofovir , microbicide gel form , HIV uninfected pregnant woman expect deliver cesarean .</brief_summary>
	<brief_title>Blood Levels Tenofovir Gel HIV Uninfected Pregnant Women Planning Cesarean Delivery</brief_title>
	<detailed_description>There urgent need HIV prevention method woman initiate control . Topical microbicides represent one method . Tenofovir 1 % vaginal gel choose high priority microbicide candidate due activity target cell HIV infection vagina cervix low frequency local systemic toxicity observe prior HIV Prevention Trials Network ( HPTN ) trial utilize tenofovir 1 % gel . The purpose study assess term pregnancy single-dose pharmacokinetics ( PK ) tenofovir 1 % gel HIV uninfected pregnant woman . The expected duration participation individually enrol participant depend early enroll prior date cesarean section , may range approximately 3 6 week . An initial screening/enrollment visit occur approximately 1 4 week prior participant 's schedule cesarean section , 4 week delivery date . A targeted physical exam , medical medication history assessment , blood urine collection , pelvic exam occur screening/enrollment . Tenofovir gel administer vaginally approximately 2 hour expect time cesarean section . On day gel administration cesarean delivery , target physical exam , medical medication history assessment , pelvic exam , maternal blood tenofovir level measurement , collection placental endometrial tissue , cord blood , amniotic fluid occur . After gel administration , PK measure take Hours 1 , 2 , 4 , 6 , 8 , 12 ; maternal blood tenofovir level measurement review adverse event also occur time . A 24-hour evaluation occur Hours 22 26 . At evaluation , target physical exam , review adverse event , tenofovir level measurement occur . Each participant contact Days 10 18 collect data adverse event experience . In addition , unscheduled visit may necessary unresolved adverse event occur 24-hour evaluation . If unscheduled visit require , participant undergo target physical exam , medical medication history assessment , blood urine collection , pelvic exam , tenofovir level measurement .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>General good health HIV uninfected Hepatitis B surface antigen negative screening enrollment Viable , single pregnancy deliver cesarean section plan 37 0/7 41 6/7 week pregnancy Normal Pap smear 12 month prior study entry Willing abstain vaginal , anal , receptive oral sex least 2 week gel administration Willing abstain intravaginal product practice ( include douche ) study participation Maternal fetal condition require urgent cesarean section Documented rupture amniotic membrane Known disease mother predictable negative effect placental function Known placental/fetal abnormality could affect placental transfer . More information criterion find protocol . Previously demonstrate hypersensitivity component tenofovir 1 % gel Certain abnormal laboratory value Use vaginal medication within 48 hour study entry Untreated sexually transmit infection ( STI ) exposure partner 's STI , include chlamydia , gonorrhea , trichomoniasis , nongonococcal urethritis Symptomatic vaginitis , include bacterial vaginosis vulvovaginal candidiasis . Participants asymptomatic sign bacterial vaginosis and/or yeast exclude . Participation investigational drug device trial within 30 day study entry Any social medical condition , opinion investigator , would interfere study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Microbicide</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>